Skip to main content
Neurology: Clinical Practice logoLink to Neurology: Clinical Practice
. 2020 Apr;10(2):90. doi: 10.1212/CPJ.0000000000000818

Reader response: Symptom burden among individuals with Parkinson disease: A national survey

Geke M Overvliet 1, Roos E Meijer van Dun 2, Indrag K Lampe 3, Annemarie M Vlaar 4
PMCID: PMC7156186  PMID: 32309021

We read with great interest the study by Tarolli et al.,1 which explored the burden of disease in Parkinson disease (PD) by evaluating the prevalence of nonmotor symptoms and their association with quality of life. The authors selected nonmotor symptoms based on literature review, expert opinions, and patient interviews. We note that apathy, which has major consequences for patients and carers, was not included as a relevant nonmotor symptom in their study. We performed a subcohort analysis of 60 patients from a study of pain in PD in 110 outpatients (PaCoMo-study, registered trial number: NL6311402917 [toetsingonline.nl]). We retrospectively reviewed the medical records to check whether the clinician identified apathy in these patients in the previous year, which was the case in 15% of the patients (n = 9). Blind to those results, patients were examined with the Apathy Scale (AS).2 In total, 63.3% (n = 38) of the patients scored positive on the AS. Only 18.4% of the patients who scored positive on the AS were also classified or mentioned with apathy in the medical records by clinicians.

Apathy, an important nonmotor symptom of PD, is often missed or minimized by clinicians. When apathy is acknowledged, treatment can lead to better outcomes for patients.3

Footnotes

Author disclosures are available upon request (ncpjournal@neurology.org)

Contributor Information

Geke M. Overvliet, (Amsterdam, the Netherlands)

Roos E. Meijer van Dun, (Amsterdam, the Netherlands)

Indrag K. Lampe, (Amsterdam, the Netherlands)

Annemarie M. Vlaar, (Amsterdam, the Netherlands)

References

  • 1.Tarolli CG, Zimmerman GA, Auinger P, et al. Symptom burden among individuals with Parkinson disease: a national survey. Neurol Clin Pract 2020;10:65–72. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Starkstein SE, Mayberg HS, Preziosi TJ, Andrezejewski P, Leiguarda R, Robinson RG. Reliability, validity, and clinical correlates of apathy in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992;4:134–139. [DOI] [PubMed] [Google Scholar]
  • 3.Devos D, Moreau C, Maltête D, et al. Rivastigmine in apathetic but dementia and depression-free patients with Parkinson's disease: a double-blind, placebo-controlled, randomised clinical trial. J Neurol Neurosurg Psychiatry 2014;85:668–674. [DOI] [PubMed] [Google Scholar]

Articles from Neurology: Clinical Practice are provided here courtesy of American Academy of Neurology

RESOURCES